Progress and prospects for blood-stage malaria vaccines

Expert Review of Vaccines

Volumn 15, Issue 6, 2016, Pages 765-781

  Miura, Kazutoyo ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

blood stage; challenge models; clinical trial; in vitro assays; Malaria; Plasmodium falciparum; vaccine

Indexed keywords

APICAL MEMBRANE ANTIGEN 1; COMBINATION B VACCINE; EBA 175; GMZ2 VACCINE; MALARIA VACCINE; MSP1 VACCINE; MSP3 VACCINE; P 27A; PARASITE ANTIGEN; RETICULOCYTE BINDING LIKE HOMOLOGUE 5; SE36 VACCINE; UNCLASSIFIED DRUG;

ANTIBODY DEPENDENT CELLULAR INHIBITION; ASSAY; DRUG EFFICACY; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; GROWTH INHIBITION; GROWTH INHIBITION ASSAY; HAPLORHINI; HUMAN; IMMUNOASSAY; IMMUNOFLUORESCENCE TEST; INVASION INHIBITION ASSAY; MALARIA; MOUSE MODEL; NONHUMAN; OPSONIZATION; PHAGOCYTOSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; VACCINATION; WESTERN BLOTTING; CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; IMMUNOLOGY; ISOLATION AND PURIFICATION; TRENDS;

CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; HUMANS; MALARIA; MALARIA VACCINES;

EID: 84958048322     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2016.1141680     Document Type: Review

References (164)

1. WHO. World Malaria Report 2014; [cited 23Oct 2015]. Available from: http://www.who.int/malaria/publications/world_malaria_report_2014/en/
2. S.Bhatt, D.J.Weiss, E.Cameron, et al. The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015. Nature. 2015;526:207–211.
3. N.J.White, S.Pukrittayakamee, T.T.Hien, et al. Malaria. Lancet. 2014;383:723–735.
4. D.C.Kaslow, S.Biernaux RTS, S: toward a first landmark on the Malaria Vaccine Technology Roadmap. Vaccine. 2015 pii: S0264-410X(15)01337-7. doi:10.1016/j.vaccine.2015.09.061.
5. RTS,S Clinical Trials Partnership. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet. 2015;386:31–45.
6. M.T.White, R.Verity, J.T.Griffin, et al. Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial. Lancet Infect Dis. 2015 pii: S1473-3099(15)00239-X. doi:10.1016/S1473-3099(15)00239-X.
7. K.Marsh, S.Kinyanjui. Immune effector mechanisms in malaria. Parasite Immunol. 2006;28:51–60.
8. S.Cohen, G.I.Mc, S.Carrington. Gamma-globulin and acquired immunity to human malaria. Nature. 1961;192:733–737.•• The first passive transfer study in human. The study has shown that antibody is the main player of protective immunity against blood-stage malaria.
9. A.Sabchareon, T.Burnouf, D.Ouattara, et al. Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. Am J Trop Med Hyg. 1991;45:297–308.• The second passive transfer study in human. The study has shown that antibodies from Africa can kill parasites in Thai.
10. WHO. Malaria Vaccine Technology Roadmap November 2013; [cited 23Oct 2015]. Available from: http://www.who.int/immunization/topics/malaria/vaccine_roadmap/en/
11. N.Tuikue-Ndam, P.Deloron. Developing vaccines to prevent malaria in pregnant women. Expert Opin Biol Ther. 2015;15:1173–1182.
12. I.Mueller, A.R.Shakri, C.E.Chitnis. Development of vaccines for Plasmodium vivax malaria. Vaccine. 2015 pii: S0264-410X(15)01336-5. doi:10.1016/j.vaccine.2015.09.060.
13. C.Morrison. Landmark green light for Mosquirix malaria vaccine. Nat Biotechnol. 2015;33:1015–1016.
14. P.D.Crompton, M.A.Kayala, B.Traore, et al. A prospective analysis of the Ab response to Plasmodium falciparum before and after a malaria season by protein microarray. Proc Natl Acad Sci U S A. 2010;107:6958–6963.
15. E.Malkin, J.Hu, Z.Li, et al. A phase 1 trial of PfCP2.9: an AMA1/MSP1 chimeric recombinant protein vaccine for Plasmodium falciparum malaria. Vaccine. 2008;26:6864–6873.
16. J.Hu, Z.Chen, J.Gu, et al. Safety and immunogenicity of a malaria vaccine, Plasmodium falciparum AMA-1/MSP-1 chimeric protein formulated in montanide ISA 720 in healthy adults. PLoS One. 2008;3:e1952.
17. F.J.Fowkes, J.S.Richards, J.A.Simpson, et al. The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: a systematic review and meta-analysis. PLoS Med. 2010;7:e1000218.• This meta-analysis study has clearly shown the interpretation of immune correlates of protection in epidemiological studies is complicated.
18. C.J.Duncan, A.V.Hill. Can growth inhibition assays (GIA) predict blood-stage malaria vaccine efficacy? Hum Vaccin Immunother. 2012;8:706–714.
19. J.S.Richards, D.I.Stanisic, F.J.Fowkes, et al. Association between naturally acquired antibodies to erythrocyte-binding antigens of Plasmodium falciparum and protection from malaria and high-density parasitemia. Clin Infect Dis. 2010;51:e50–60.
20. J.Rono, F.H.Osier, D.Olsson, et al. Breadth of anti-merozoite antibody responses is associated with the genetic diversity of asymptomatic Plasmodium falciparum infections and protection against clinical malaria. Clin Infect Dis. 2013;57:1409–1416.
21. D.K.Moss, E.J.Remarque, B.W.Faber, et al. Plasmodium falciparum 19-kilodalton merozoite surface protein 1 (MSP1)-specific antibodies that interfere with parasite growth in vitro can inhibit MSP1 processing, merozoite invasion, and intracellular parasite development. Infect Immun. 2012;80:1280–1287.
22. E.S.Bergmann-Leitner, E.H.Duncan, G.E.Mullen, et al. Critical evaluation of different methods for measuring the functional activity of antibodies against malaria blood stage antigens. Am J Trop Med Hyg. 2006;75:437–442.
23. E.M.Malkin, D.J.Diemert, J.H.McArthur, et al. Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria. Infect Immun. 2005;73:3677–3685.
24. M.E.Polhemus, A.J.Magill, J.F.Cummings, et al. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research. Vaccine. 2007;25:4203–4212.
25. M.Roestenberg, E.Remarque, E.De Jonge, et al. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02. PLoS One. 2008;3:e3960.
26. R.D.Ellis, L.B.Martin, D.Shaffer, et al. Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria naive adults. PLoS One. 2010;5:e8787.
27. H.M.El Sahly, S.M.Patel, R.L.Atmar, et al. Safety and immunogenicity of a recombinant nonglycosylated erythrocyte binding antigen 175 Region II malaria vaccine in healthy adults living in an area where malaria is not endemic. Clin Vaccine Immunol. 2010;17:1552–1559.
28. A.Dicko, D.J.Diemert, I.Sagara, et al. Impact of a Plasmodium falciparum AMA1 vaccine on antibody responses in adult Malians. PLoS One. 2007;2:e1045.
29. M.A.Thera, O.K.Doumbo, D.Coulibaly, et al. Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a phase 1 randomized controlled trial. PLoS One. 2008;3:e1465.
30. K.Miura, H.Zhou, A.Diouf, et al. Immunological responses against Plasmodium falciparum Apical Membrane Antigen 1 vaccines vary depending on the population immunized. Vaccine. 2011;29:2255–2261.
31. K.Miura, S.Perera, S.Brockley, et al. Non-Apical Membrane Antigen 1 (AMA1) IgGs from Malian children interfere with functional activity of AMA1 IgGs as judged by growth inhibition assay. PLoS One. 2011;6:e20947.
32. K.Miura, H.Zhou, S.E.Moretz, et al. Comparison of biological activity of human anti-apical membrane antigen-1 antibodies induced by natural infection and vaccination. J Immunol. 2008;181:8776–8783.
33. C.J.Duncan, S.H.Sheehy, K.J.Ewer, et al. Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/Alhydrogel+CPG 7909. PLoS One. 2011;6:e22271.
34. S.Dutta, J.S.Sullivan, K.K.Grady, et al. High antibody titer against apical membrane antigen-1 is required to protect against malaria in the Aotus model. PLoS One. 2009;4:e8138.
35. S.Singh, K.Miura, H.Zhou, et al. Immunity to recombinant Plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity. Infect Immun. 2006;74:4573–4580.
36. M.J.Boyle, L.Reiling, G.Feng, et al. Human antibodies fix complement to inhibit Plasmodium falciparum invasion of erythrocytes and are associated with protection against malaria. Immunity. 2015;42:580–590.
37. M.J.Boyle, D.W.Wilson, J.S.Richards, et al. Isolation of viable Plasmodium falciparum merozoites to define erythrocyte invasion events and advance vaccine and drug development. Proc Natl Acad Sci U S A. 2010;107:14378–14383.
38. H.Bouharoun-Tayoun, C.Oeuvray, F.Lunel, et al. Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages. J Exp Biol. 1995;182:409–418.
39. H.Bouharoun-Tayoun, P.Attanath, A.Sabchareon, et al. Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes. J Exp Med. 1990;172:1633–1641.
40. J.S.McCarthy, J.Marjason, S.Elliott, et al. A phase 1 trial of MSP2-C1, a blood-stage malaria vaccine containing 2 isoforms of MSP2 formulated with Montanide ISA 720. PLoS One. 2011;6:e24413.
41. P.Druilhe, F.Spertini, D.Soesoe, et al. A malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparum. PLoS Med. 2005;2:e344.
42. C.C.Hermsen, D.F.Verhage, D.S.Telgt, et al. Glutamate-rich protein (GLURP) induces antibodies that inhibit in vitro growth of Plasmodium falciparum in a phase 1 malaria vaccine trial. Vaccine. 2007;25:2930–2940.
43. M.Yagi, G.Bang, T.Tougan, et al. Protective epitopes of the Plasmodium falciparum SERA5 malaria vaccine reside in intrinsically unstructured N-terminal repetitive sequences. PLoS One. 2014;9:e98460.
44. P.Chimma, C.Roussilhon, P.Sratongno, et al. A distinct peripheral blood monocyte phenotype is associated with parasite inhibitory activity in acute uncomplicated Plasmodium falciparum malaria. PLoS Pathog. 2009;5:e1000631.
45. Y.P.Shi, V.Udhayakumar, A.J.Oloo, et al. Differential effect and interaction of monocytes, hyperimmune sera, and immunoglobulin G on the growth of asexual stage Plasmodium falciparum parasites. Am J Trop Med Hyg. 1999;60:135–141.
46. R.W.Tiendrebeogo, B.Adu, S.K.Singh, et al. High-throughput tri-colour flow cytometry technique to assess Plasmodium falciparum parasitaemia in bioassays. Malar J. 2014;13:412.
47. D.L.Hill, E.M.Eriksson, C.S.Li Wai Suen, et al. Opsonising antibodies to P. falciparum merozoites associated with immunity to clinical malaria. PLoS One. 2013;8:e74627.
48. F.H.Osier, G.Feng, M.J.Boyle, et al. Opsonic phagocytosis of Plasmodium falciparum merozoites: mechanism in human immunity and a correlate of protection against malaria. BMC Med. 2014;12:108.
49. A.Ghumra, P.Khunrae, R.Ataide, et al. Immunisation with recombinant PfEMP1 domains elicits functional rosette-inhibiting and phagocytosis-inducing antibodies to Plasmodium falciparum. PLoS One. 2011;6:e16414.
50. J.A.Chan, K.B.Howell, L.Reiling, et al. Targets of antibodies against Plasmodium falciparum-infected erythrocytes in malaria immunity. J Clin Invest. 2012;122:3227–3238.
51. J.Zhou, G.Feng, J.Beeson, et al. CD14(hi)CD16+ monocytes phagocytose antibody-opsonised Plasmodium falciparum infected erythrocytes more efficiently than other monocyte subsets, and require CD16 and complement to do so. BMC Med. 2015;13:154.
52. H.B.Fleit, C.D.Kobasiuk. The human monocyte-like cell line THP-1 expresses Fc gamma RI and Fc gamma RII. J Leukoc Biol. 1991;49:556–565.
53. P.R.Gilson, B.S.Crabb. Morphology and kinetics of the three distinct phases of red blood cell invasion by Plasmodium falciparum merozoites. Int J Parasitol. 2009;39:91–96.
54. M.J.Boyle, D.W.Wilson, J.S.Richards, et al. Isolation of viable Plasmodium falciparum merozoites to define erythrocyte invasion events and advance vaccine and drug development. Proc Natl Acad Sci USA. 2010;107:14378–14383.
55. J.A.Chan, F.J.Fowkes, J.G.Beeson. Surface antigens of Plasmodium falciparum-infected erythrocytes as immune targets and malaria vaccine candidates. Cell Mol Life Sci. 2014;71:3633–3657.
56. A.Bengtsson, L.Joergensen, T.S.Rask, et al. A novel domain cassette identifies Plasmodium falciparum PfEMP1 proteins binding ICAM-1 and is a target of cross-reactive, adhesion-inhibitory antibodies. J Immunol. 2013;190:240–249.
57. D.Angeletti, L.Albrecht, M.Wahlgren, et al. Analysis of antibody induction upon immunization with distinct NTS-DBL1alpha-domains of PfEMP1 from rosetting Plasmodium falciparum parasites. Malar J. 2013;12:32.
58. M.Guillotte, A.Juillerat, S.Igonet, et al. Immunogenicity of the Plasmodium falciparum PfEMP1-VarO adhesin: induction of surface-reactive and rosette-disrupting antibodies to VarO infected erythrocytes. PLoS One. 2015;10:e0134292.
59. L.Hviid, A.T.Jensen. PfEMP1 - a parasite protein family of key importance in Plasmodium falciparum malaria immunity and pathogenesis. Adv Parasitol. 2015;88:51–84.
60. C.Joos, L.Marrama, H.E.Polson, et al. Clinical protection from falciparum malaria correlates with neutrophil respiratory bursts induced by merozoites opsonized with human serum antibodies. PLoS One. 2010;5:e9871.
61. D.Llewellyn, K.Miura, M.P.Fay, et al. Standardization of the antibody-dependent respiratory burst assay with human neutrophils and Plasmodium falciparum malaria. Sci Rep. 2015;5:14081.
62. D.I.Baruch, B.Gamain, L.H.Miller. DNA immunization with the cysteine-rich interdomain region 1 of the Plasmodium falciparum variant antigen elicits limited cross-reactive antibody responses. Infect Immun. 2003;71:4536–4543.
63. J.Gullingsrud, T.Saveria, E.Amos, et al. Structure-function-immunogenicity studies of PfEMP1 domain DBL2betaPF11_0521, a malaria parasite ligand for ICAM-1. PLoS One. 2013;8:e61323.
64. A.Jeppesen, S.B.Ditlev, V.Soroka, et al. Multiple Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) variants per genome can bind IgM via Fcμ. Infect Immun. 2015;83:3972–3981.
65. F.Lennartz, A.Bengtsson, R.W.Olsen, et al. Mapping the binding site of a cross-reactive Plasmodium falciparum PfEMP1 monoclonal antibody inhibitory of ICAM-1 binding. J Immunol. 2015;195:3273–3283.
66. C.F.Ockenhouse, E.Angov, K.E.Kester, et al. Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine. Vaccine. 2006;24:3009–3017.
67. I.Nebie, A.Diarra, A.Ouedraogo, et al. Humoral and cell-mediated immunity to MSP3 peptides in adults immunized with MSP3 in malaria endemic area, Burkina Faso. Parasite Immunol. 2009;31:474–480.
68. M.D.Spring, J.F.Cummings, C.F.Ockenhouse, et al. Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A. PLoS One. 2009;4:e5254.
69. S.H.Sheehy, C.J.Duncan, S.C.Elias, et al. Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. PLoS One. 2012;7:e31208.
70. S.H.Hodgson, P.Choudhary, S.C.Elias, et al. Combining viral vectored and protein-in-adjuvant vaccines against the blood-stage malaria antigen AMA1 - report on a phase Ia clinical trial. Mol Ther. 2014;22:2142–2154.
71. D.J.Pombo, G.Lawrence, C.Hirunpetcharat, et al. Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet. 2002;360:610–617.
72. M.D.Edstein, B.M.Kotecka, K.L.Anderson, et al. Lengthy antimalarial activity of atovaquone in human plasma following atovaquone-proguanil administration. Antimicrob Agents Chemother. 2005;49:4421–4422.
73. W.E.Collins, A.Walduck, J.S.Sullivan, et al. Efficacy of vaccines containing rhoptry-associated proteins RAP1 and RAP2 of Plasmodium falciparum in Saimiri boliviensis monkeys. Am J Trop Med Hyg. 2000;62:466–479.
74. A.W.Stowers, M.C.Kennedy, B.P.Keegan, et al. Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malaria. Infect Immun. 2002;70:6961–6967.
75. L.J.Carvalho, S.G.Oliveira, M.Theisen, et al. Immunization of Saimiri sciureus monkeys with Plasmodium falciparum merozoite surface protein-3 and glutamate-rich protein suggests that protection is related to antibody levels. Scand J Immunol. 2004;59:363–372.
76. M.E.Patarroyo, M.P.Alba, H.Curtidor, et al. Using the PfEMP1 head structure binding motif to deal a blow at severe malaria. PLoS One. 2014;9:e88420.
77. A.D.Douglas, A.R.Williams, E.Knuepfer, et al. Neutralization of Plasmodium falciparum merozoites by antibodies against PfRH5. J Immunol. 2014;192:245–258.
78. A.W.Stowers, L.H.Miller. Are trials in New World monkeys on the critical path for blood-stage malaria vaccine development? Trends Parasitol. 2001;17:415–419.
79. S.Herrera, B.L.Perlaza, A.Bonelo, et al. Aotus monkeys: their great value for anti-malaria vaccines and drug testing. Int J Parasitol. 2002;32:1625–1635.
80. D.Sturchler, R.Berger, C.Rudin, et al. Safety, immunogenicity, and pilot efficacy of Plasmodium falciparum sporozoite and asexual blood-stage combination vaccine in Swiss adults. Am J Trop Med Hyg. 1995;53:423–431.
81. C.F.Ockenhouse, P.F.Sun, D.E.Lanar, et al. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. J Infect Dis. 1998;177:1664–1673.
82. M.Sedegah, C.Tamminga, S.McGrath, et al. Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults. PLoS One. 2011;6:e24586.
83. F.M.Thompson, D.W.Porter, S.L.Okitsu, et al. Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial. PLoS One. 2008;3:e1493.
84. C.Tamminga, M.Sedegah, S.Maiolatesi, et al. Human adenovirus 5-vectored Plasmodium falciparum NMRC-M3V-Ad-PfCA vaccine encoding CSP and AMA1 is safe, well-tolerated and immunogenic but does not protect against controlled human malaria infection. Hum Vaccin Immunother. 2013;9:2165–2177.
85. S.H.Sheehy, C.J.Duncan, S.C.Elias, et al. ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans. Mol Ther. 2012;20:2355–2368.
86. G.Lawrence, Q.Q.Cheng, C.Reed, et al. Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers. Vaccine. 2000;18:1925–1931.
87. R.W.Sauerwein, M.Roestenberg, V.S.Moorthy. Experimental human challenge infections can accelerate clinical malaria vaccine development. Nat Rev Immunol. 2010;11:57–64.
88. C.R.Engwerda, G.Minigo, F.H.Amante, et al. Experimentally induced blood stage malaria infection as a tool for clinical research. Trends Parasitol. 2012;28:515–521.
89. S.H.Sheehy, A.D.Douglas, S.J.Draper. Challenges of assessing the clinical efficacy of asexual blood-stage Plasmodium falciparum malaria vaccines. Hum Vaccin Immunother. 2013;9:1831–1840.
90. A.C.Teirlinck, M.Roestenberg, M.Van De Vegte-Bolmer, et al. NF135.C10: a new Plasmodium falciparum clone for controlled human malaria infections. J Infect Dis. 2012;207:656–660.
91. D.I.Stanisic, X.Q.Liu, S.L.De, et al. Development of cultured Plasmodium falciparum blood-stage malaria cell banks for early phase in vivo clinical trial assessment of anti-malaria drugs and vaccines. Malar J. 2015;14:143.
92. E.Siu, A.Ploss. Modeling malaria in humanized mice: opportunities and challenges. Ann N Y Acad Sci. 2015;1342:29–36.
93. Q.Chen, A.Amaladoss, W.Ye, et al. Human natural killer cells control Plasmodium falciparum infection by eliminating infected red blood cells. Proc Natl Acad Sci U S A. 2014;111:1479–1484.
94. W.Wijayalath, S.Majji, E.F.Villasante, et al. Humanized HLA-DR4.RagKO.IL2RgammacKO.NOD (DRAG) mice sustain the complex vertebrate life cycle of Plasmodium falciparum malaria. Malar J. 2014;13:386.
95. J.Huang, X.Li, J.G.Coelho-Dos-Reis, et al. Human immune system mice immunized with Plasmodium falciparum circumsporozoite protein induce protective human humoral immunity against malaria. J Immunol Methods. 2015 pii: S0022-1759(15)30047-8. doi:10.1016/j.jim.2015.09.005.
96. B.Genton, I.Betuela, I.Felger, et al. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J Infect Dis. 2002;185:820–827.•• The first phase II blood-stage vaccine trial which showed a strain-specific efficacy in the field.
97. M.A.Thera, O.K.Doumbo, D.Coulibaly, et al. A field trial to assess a blood-stage malaria vaccine. N Engl J Med. 2011;365:1004–1013.•• The phase II blood-stage vaccine trial which showed a strain-specific protective efficacy in the field.
98. S.B.Sirima, S.Cousens, P.Druilhe. Protection against malaria by MSP3 candidate vaccine. N Engl J Med. 2011;365:1062–1064.• A phase I blood-stage vaccine trial which showed a significant efficacy in the field.
99. N.M.Palacpac, E.Ntege, A.Yeka, et al. Phase 1b randomized trial and follow-up study in Uganda of the blood-stage malaria vaccine candidate BK-SE36. PLoS One. 2013;8:e64073.• A phase I blood-stage vaccine trial which showed a significant efficacy in the field.
100. WHO. Malaria rainbow tables; [cited 2015 Oct23]. Available from: http://www.who.int/immunization/research/development/Rainbow_tables/en/
101. ClinicalTrial.gov; [cited 2015 Oct23]. Available from: https://clinicaltrials.gov/
102. M.B.Laurens, M.A.Thera, D.Coulibaly, et al. Extended safety, immunogenicity and efficacy of a blood-stage malaria vaccine in Malian children: 24-month follow-up of a randomized, double-blinded phase 2 trial. PLoS One. 2013;8:e79323.
103. I.Sagara, A.Dicko, R.D.Ellis, et al. A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali. Vaccine. 2009;27:3090–3098.
104. A.Ouattara, J.Mu, S.Takala-Harrison, et al. Lack of allele-specific efficacy of a bivalent AMA1 malaria vaccine. Malar J. 2010;9:175.
105. G.E.Mullen, R.D.Ellis, K.Miura, et al. Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria. PLoS One. 2008;3:e2940.
106. D.R.Drew, A.N.Hodder, D.W.Wilson, et al. Defining the antigenic diversity of Plasmodium falciparum apical membrane antigen 1 and the requirements for a multi-allele vaccine against malaria. PLoS One. 2012;7:e51023.
107. S.Dutta, L.S.Dlugosz, D.R.Drew, et al. Overcoming antigenic diversity by enhancing the immunogenicity of conserved epitopes on the malaria vaccine candidate apical membrane antigen-1. PLoS Pathog. 2013;9:e1003840.
108. K.Miura, R.Herrera, A.Diouf, et al. Overcoming allelic specificity by immunization with five allelic forms of Plasmodium falciparum apical membrane antigen 1. Infect Immun. 2013;81:1491–1501.
109. K.A.Kusi, B.W.Faber, M.Van Der Eijk, et al. Immunization with different PfAMA1 alleles in sequence induces clonal imprint humoral responses that are similar to responses induced by the same alleles as a vaccine cocktail in rabbits. Malar J. 2011;10:40.
110. K.A.Kusi, E.J.Remarque, V.Riasat, et al. Safety and immunogenicity of multi-antigen AMA1-based vaccines formulated with CoVaccine HTTM and Montanide ISA 51 in rhesus macaques. Malar J. 2011;10:182.
111. K.S.Harris, C.G.Adda, M.Khore, et al. Use of immunodampening to overcome diversity in the malarial vaccine candidate apical membrane antigen 1. Infect Immun. 2014;82:4707–4717.
112. D.Richard, C.A.Macraild, D.T.Riglar, et al. Interaction between Plasmodium falciparum apical membrane antigen 1 and the Rhoptry neck protein complex defines a key step in the erythrocyte invasion process of malaria parasites. J Biol Chem. 2010;285:14815–14822.
113. P.Srinivasan, E.Ekanem, A.Diouf, et al. Immunization with a functional protein complex required for erythrocyte invasion protects against lethal malaria. Proc Natl Acad Sci U S A. 2014;111:10311–10316.
114. C.W.Tsai, P.F.Duggan, A.J.Jin, et al. Characterization of a protective Escherichia coli-expressed Plasmodium falciparum merozoite surface protein 3 indicates a non-linear, multi-domain structure. Mol Biochem Parasitol. 2009;164:45–56.
115. R.Audran, M.Cachat, F.Lurati, et al. Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen. Infect Immun. 2005;73:8017–8026.
116. M.P.Jepsen, P.S.Jogdand, S.K.Singh, et al. The malaria vaccine candidate GMZ2 elicits functional antibodies in individuals from malaria-endemic and non-endemic areas. J Infect Dis. 2013;208:479–488.
117. M.Esen, P.G.Kremsner, R.Schleucher, et al. Safety and immunogenicity of GMZ2 - a MSP3-GLURP fusion protein malaria vaccine candidate. Vaccine. 2009;27:6862–6868.
118. B.Mordmuller, K.Szywon, B.Greutelaers, et al. Safety and immunogenicity of the malaria vaccine candidate GMZ2 in malaria-exposed, adult individuals from Lambarene, Gabon. Vaccine. 2010;28:6698–6703.
119. S.Belard, S.Issifou, A.B.Hounkpatin, et al. A randomized controlled phase Ib trial of the malaria vaccine candidate GMZ2 in African children. PLoS One. 2011;6:e22525.
120. T.Horii, H.Shirai, L.Jie, et al. Evidences of protection against blood-stage infection of Plasmodium falciparum by the novel protein vaccine SE36. Parasitol Int. 2010;59:380–386.
121. C.A.Darko, E.Angov, W.E.Collins, et al. The clinical-grade 42-kilodalton fragment of merozoite surface protein 1 of Plasmodium falciparum strain FVO expressed in Escherichia coli protects Aotus nancymai against challenge with homologous erythrocytic-stage parasites. Infect Immun. 2005;73:287–297.
122. J.A.Lyon, E.Angov, M.P.Fay, et al. Protection induced by Plasmodium falciparum MSP1(42) is strain-specific, antigen and adjuvant dependent, and correlates with antibody responses. PLoS One. 2008;3:e2830.
123. B.R.Ogutu, O.J.Apollo, D.McKinney, et al. Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya. PLoS One. 2009;4:e4708.
124. J.Healer, J.K.Thompson, D.T.Riglar, et al. Vaccination with conserved regions of erythrocyte-binding antigens induces neutralizing antibodies against multiple strains of Plasmodium falciparum. PLoS One. 2013;8:e72504.
125. A.K.Bei, C.D.Membi, J.C.Rayner, et al. Variant merozoite protein expression is associated with erythrocyte invasion phenotypes in Plasmodium falciparum isolates from Tanzania. Mol Biochem Parasitol. 2007;153:66–71.
126. V.Villard, G.W.Agak, G.Frank, et al. Rapid identification of malaria vaccine candidates based on alpha-helical coiled coil protein motif. PLoS One. 2007;2:e645.
127. C.Kulangara, S.Luedin, O.Dietz, et al. Cell biological characterization of the malaria vaccine candidate trophozoite exported protein 1. PLoS One. 2012;7:e46112.
128. S.Olugbile, C.Kulangara, G.Bang, et al. Vaccine potentials of an intrinsically unstructured fragment derived from the blood stage associated P. falciparum protein PFF0165c. Infect Immun. 2009;77:5701–5709.
129. A.D.Douglas, A.R.Williams, J.J.Illingworth, et al. The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody. Nat Commun. 2011;2:601.
130. T.M.Tran, A.Ongoiba, J.Coursen, et al. Naturally acquired antibodies specific for Plasmodium falciparum reticulocyte-binding protein homologue 5 inhibit parasite growth and predict protection from malaria. J Infect Dis. 2014;209:789–798.
131. S.D.Patel, A.D.Ahouidi, A.K.Bei, et al. Plasmodium falciparum merozoite surface antigen, PfRH5, elicits detectable levels of invasion-inhibiting antibodies in humans. J Infect Dis. 2013;208:1679–1687.
132. L.Y.Bustamante, S.J.Bartholdson, C.Crosnier, et al. A full-length recombinant Plasmodium falciparum PfRH5 protein induces inhibitory antibodies that are effective across common PfRH5 genetic variants. Vaccine. 2013;31:373–379.
133. A.D.Douglas, G.C.Baldeviano, C.M.Lucas, et al. A PfRH5-based vaccine is efficacious against heterologous strain blood-stage Plasmodium falciparum infection in Aotus monkeys. Cell Host Microbe. 2015;17:130–139.
134. L.Chen, S.Lopaticki, D.T.Riglar, et al. An EGF-like protein forms a complex with PfRh5 and is required for invasion of human erythrocytes by Plasmodium falciparum. PLoS Pathog. 2011;7:e1002199.
135. K.S.Reddy, E.Amlabu, A.K.Pandey, et al. Multiprotein complex between the GPI-anchored CyRPA with PfRH5 and PfRipr is crucial for Plasmodium falciparum erythrocyte invasion. Proc Natl Acad Sci U S A. 2015;112:1179–1184.
136. A.R.Williams, A.D.Douglas, K.Miura, et al. Enhancing blockade of Plasmodium falciparum erythrocyte invasion: assessing combinations of antibodies against PfRH5 and other merozoite antigens. PLoS Pathog. 2012;8:e1002991.
137. K.S.Reddy, A.K.Pandey, H.Singh, et al. Bacterially expressed full-length recombinant Plasmodium falciparum RH5 protein binds erythrocytes and elicits potent strain-transcending parasite-neutralizing antibodies. Infect Immun. 2014;82:152–164.
138. J.S.Richards, T.U.Arumugam, L.Reiling, et al. Identification and prioritization of merozoite antigens as targets of protective human immunity to Plasmodium falciparum malaria for vaccine and biomarker development. J Immunol. 2013;191:795–809.
139. F.H.Osier, M.J.Mackinnon, C.Crosnier, et al. New antigens for a multicomponent blood-stage malaria vaccine. Sci Transl Med. 2014;6:247ra102.
140. D.K.Raj, C.P.Nixon, C.E.Nixon, et al. Antibodies to PfSEA-1 block parasite egress from RBCs and protect against malaria infection. Science. 2014;344:871–877.
141. N.Ahlborg, J.Iqbal, L.Bjork, et al. Plasmodium falciparum: differential parasite growth inhibition mediated by antibodies to the antigens Pf332 and Pf155/RESA. Exp Parasitol. 1996;82:155–163.
142. H.A.Balogun, N.W.Awah, S.E.Farouk, et al. Pf332-C231-reactive antibodies affect growth and development of intra-erythrocytic Plasmodium falciparum parasites. Vaccine. 2011;30:21–28.
143. H.D.De Silva, S.Saleh, S.Kovacevic, et al. The antibody response to Plasmodium falciparum merozoite surface protein 4: comparative assessment of specificity and growth inhibitory antibody activity to infection-acquired and immunization-induced epitopes. Malar J. 2011;10:266.
144. X.Zhao, Z.Chang, Z.Tu, et al. PfRON3 is an erythrocyte-binding protein and a potential blood-stage vaccine candidate antigen. Malar J. 2014;13:490.
145. T.U.Arumugam, S.Takeo, T.Yamasaki, et al. Discovery of GAMA, a Plasmodium falciparum merozoite micronemal protein, as a novel blood-stage vaccine candidate antigen. Infect Immun. 2011;79:4523–4532.
146. X.Li, M.Marinkovic, C.Russo, et al. Identification of a specific region of Plasmodium falciparum EBL-1 that binds to host receptor glycophorin B and inhibits merozoite invasion in human red blood cells. Mol Biochem Parasitol. 2012;183:23–31.
147. H.Sakamoto, S.Takeo, A.G.Maier, et al. Antibodies against a Plasmodium falciparum antigen PfMSPDBL1 inhibit merozoite invasion into human erythrocytes. Vaccine. 2012;30:1972–1980.
148. C.Y.Chiu, A.N.Hodder, C.S.Lin, et al. Antibodies to the Plasmodium falciparum proteins MSPDBL1 and MSPDBL2 opsonise merozoites, inhibit parasite growth and predict protection from clinical malaria. J Infect Dis. 2015;212:406–415.
149. D.Ito, T.Hasegawa, K.Miura, et al. RALP1 is a rhoptry-neck erythrocyte-binding protein of Plasmodium falciparum merozoite and a potential blood-stage vaccine candidate antigen. Infect Immun. 2013;81:4290–4298.
150. R.D.Ellis, Y.Wu, L.B.Martin, et al. Phase 1 study in malaria naive adults of BSAM2/Alhydrogel(R)+CPG 7909, a blood stage vaccine against P. falciparum malaria. PLoS One. 2012;7:e46094.
151. C.E.Chitnis, P.Mukherjee, S.Mehta, et al. Phase I clinical trial of a recombinant blood stage vaccine candidate for Plasmodium falciparum malaria based on MSP1 and EBA175. PLoS One. 2015;10:e0117820.
152. P.G.Cech, T.Aebi, M.S.Abdallah, et al. Virosome-formulated Plasmodium falciparum AMA-1 & CSP derived peptides as malaria vaccine: randomized phase 1b trial in semi-immune adults & children. PLoS One. 2011;6:e22273.
153. M.Theisen, W.Roeffen, S.K.Singh, et al. A multi-stage malaria vaccine candidate targeting both transmission and asexual parasite life-cycle stages. Vaccine. 2014;32:2623–2630.
154. A.Boes, H.Spiegel, N.Voepel, et al. Analysis of a multi-component multi-stage malaria vaccine candidate-tackling the cocktail challenge. PLoS One. 2015;10:e0131456.
155. H.Spiegel, A.Boes, R.Kastilan, et al. The stage-specific in vitro efficacy of a malaria antigen cocktail provides valuable insights into the development of effective multi-stage vaccines. Biotechnol J. 2015;10:1651–1659.
156. M.F.Good, J.M.Reiman, I.B.Rodriguez, et al. Cross-species malaria immunity induced by chemically attenuated parasites. J Clin Invest. 2013;123:3353–3362.
157. R.A.Seder, L.-J.Chang, M.E.Enama, et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science. 2013;341:1359–1365.
158. K.Bojang, P.Milligan, M.Pinder, et al. Five year safety and immunogenicity of GlaxoSmithKline’s candidate malaria vaccine RTS,S/AS02 following administration to semi-immune adult men living in a malaria-endemic region of The Gambia. Hum Vaccin. 2009;5(4):242–247.
159. K.E.Kester, J.F.Cummings, O.Ofori-Anyinam, et al. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis. 2009;200:337–346.
160. M.A.Pierce, R.D.Ellis, L.B.Martin, et al. Phase 1 safety and immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-C1/ISA 720 in Australian adults. Vaccine. 2010;28:2236–2242.
161. S.Dutta, S.Y.Lee, A.H.Batchelor, et al. Structural basis of antigenic escape of a malaria vaccine candidate. Proc Natl Acad Sci U S A. 2007;104:12488–12493.
162. K.E.Wright, K.A.Hjerrild, J.Bartlett, et al. Structure of malaria invasion protein RH5 with erythrocyte basigin and blocking antibodies. Nature. 2014;515:427–430.
163. R.L.Ord, J.C.Caldeira, M.Rodriguez, et al. A malaria vaccine candidate based on an epitope of the Plasmodium falciparum RH5 protein. Malar J. 2014;13:326.
164. S.Dunachie, T.Berthoud, A.V.Hill, et al. Transcriptional changes induced by candidate malaria vaccines and correlation with protection against malaria in a human challenge model. Vaccine. 2015;33:5321–5331.